No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Raplixa is a brand of hematological drugs used to treat and prevent bleeding in patients with hemophilia A and B. It is a recombinant factor VIII (FVIII) and factor IX (FIX) therapy, respectively, and is administered via intravenous infusion. Raplixa is a long-acting therapy, meaning it can last up to 24 hours, and is designed to reduce the number of infusions needed to maintain adequate levels of FVIII and FIX. It is also designed to reduce the risk of developing inhibitors, which can occur when a patient is exposed to FVIII or FIX for a long period of time.
Raplixa is manufactured by Pfizer, Inc. and is available in the United States, Canada, and Europe. Other companies in the market include Novo Nordisk, Bayer, and CSL Behring. Show Less Read more
